Irish-listed pharma company hVIVO signs €15.2m contract

Stock market listed pharmaceutical services firm hVIVO has signed a £13.1m (€15.2m) contract with a large global pharmaceutical company to develop an influenza B virus challenge model.

Irish founded hVIVO, previously known as Open Orphan, runs drug trials known as challenge studies in its London quarantine clinic in Whitechapel.

The first stage of the agreement includes the manufacturing of an influenza B challenge virus, which has now been completed.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO